Aim of the work: To study the prevalence of anti-HCV antibodies among patients suffering from systemic lupus erythematosus (SLE) as well as to determine the impact of chronic HCV infection on the clinical manifestations and disease activity.
Introduction
Hepatitis C virus (HCV), an enveloped positive, linear, singlestranded RNA virus of the genus Hepacivirus and family Flavivirdae, was identified in 1989 and recognized as the major cause of non-A, non-B hepatitis [1] . HCV became a major public health problem, with 170 million people infected worldwide [2] . Egypt has possibly the highest HCV prevalence in the world; antibody to HCV (anti-HCV) is present in 11-14% or 8-10 million inhabitants, of whom 5-7 million have active viremia [3, 4] ; compared to the prevalence of antibodies to HCV in the United States which is approximately 1.6% according to the National Health and Nutrition Examination Survey [5] . The rate of infection varies among the different governorates in Egypt; it is lowest in Cairo and Alexandria at 8%, intermediate in rural areas along the Nile south of Cairo (Middle and Upper Egypt) at 8-16%, and highest in rural areas of Nile Delta or Lower Egypt, at 15% [4] . In a recent study, HCV antibodies were found in 18.5% among admitted patients to the rheumatology ward, Cairo University Hospitals, Egypt. The rheumatic manifestations of chronic HCV represent the primary cause of admission in 7% of all the admitted patients in that department [6] .
Systemic lupus erythematosus (SLE) is one of the common rheumatic diseases in rheumatology practice, and the association between two common diseases; chronic HCV infection and SLE may occur. Whether, there is increased prevalence of HCV infection in patients with SLE is still controversial. Antibodies to HCV were present in 18/134 Spanish patients with SLE (13%) compared to 2/200 (1%) of the blood donors studied in the same geographic area. Among the anti-HCV-positive group, HCV infection was confirmed (by RIBA-3 and PCR) in 15 SLE patients (11%) and in the 2 blood donors (1%) (p < 0.001) [7] . Thirteen of 92 SLE patients were HCV positive, while only 2 of the 58 normal controls were positive in China [8] .
In a cross sectional study in Rio de Janeiro, Brazil; HCV antibodies screening showed a significant difference between SLE patients and a blood donor control group (6.6% and 1.39% respectively). However, when confirmatory assays were subsequently applied, no difference in HCV prevalence between both groups was observed [9] . The prevalence of antibodies against HCV and HBV in SLE was not higher than in blood donors or general population in Mexico and Israel [10, 11] .
Various mechanisms were proposed to explain the association between HCV and SLE or autoimmunity in general. Out of these, viruses have been postulated as a potential etiologic or triggering agent in the pathogenesis of SLE. Persistent HCV infection can evoke autoimmune response including the production of autoantibodies through the ''molecular mimicry'' between HCV poly-proteins and self-proteins [12] . Another possible mechanism is ''bystander activation'' which proposes that the viral infection can induce local tissue inflammation resulting in the activation of auto-reactive Tcells that were dormant or suppressed by the peripheral regulatory mechanisms [13] . HCV-related autoimmunity has partly been shown to be related to the increased serum B-lymphocyte activating factor (BAFF) and/or the resistance of CD5+ Bcells subpopulation to apoptosis in chronic HCV infection [14, 15] .
The aim of this work was to determine the prevalence of HCV infection in a cohort of patients with SLE, and to identify the impact of its presence on the clinical, laboratory and immunologic features of the disease.
Patients and methods

Study population
A total of 98 consecutive SLE patients (87 females and 11 males; mean age 26.5 years, range 14-63 years; mean disease duration 4 years, range 0.25-17 years) presenting to the rheumatology department of Cairo University Hospitals were included in this study. All patients fulfilled the 1982 revised criteria of the American College of Rheumatology (ACR) for the classification of SLE [16] . All patients underwent a medical interview through a preset questionnaire including the detailed demographic data, medical history as well as a routine examination by a qualified rheumatologist. All patients were screened for HCV antibodies and confirmatory quantitative PCR testing was done for all the HCV antibody positive patients. Patients were classified into two groups according to the presence of HCV antibodies: HCV/SLE and non-HCV/SLE patients. The clinical and serologic characteristics of all patients were documented. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [17] . The Ethics Committee of the Faculty of Medicine, Cairo University; approved the study and a written informed consent was obtained from each participant.
Laboratory studies
Detection of HCV infection: All patients were screened for anti-HCV antibodies using a 3rd generation enzyme-linked immunosorbent assay (ELISA) (Innotest HCV Ab III, Innogenetics, Ghent, Belgium). All patients with positive anti-HCV were tested for the presence of HCV RNA by polymerase chain reaction (PCR; RNA extraction, reverse transcription and polymerase chain reaction with primers complementary to the 5' non-coding region of the HCV genome).
Other laboratory tests: Routine laboratory investigations were done including sedimentation rate (Westergren method), complete blood picture, total plasma protein, serum albumin, creatinine, cholesterol, triglycerides, liver function tests (serum aspartate transaminase AST; serum alanine transaminase ALT; serum total, direct and indirect bilirubin), complete urine analysis and 24 h urinary proteins. The immunologic tests included determination of the antinuclear antibodies (ANA) by immunofluorescence technique using indirect fluorescence antibody kit (ANAFAST, Diasorin; USA) utilizing tissue culture cells as a substrate for the detection and titration of the circulating antinuclear antibodies in human serum and anti-double stranded DNA antibody (anti-ds-DNA) using ELISA kit (Diasorin; USA). It is a quantitative indirect enzyme immunoassay for the detection in human serum or plasma of the IgG and IgM classes of autoantibodies specific for double-stranded DNA. IgG and IgM anticardiolipins (aCL) were estimated by ELISA technique [18, 19] . Finally, complement components (C3 and C4) were estimated by nephelometric method.
Imaging and other investigations
Chest X-ray and abdominal ultrasound were done for all patients to assess the chest, liver and kidney status; other imaging studies were done according to the suspected problems in each case. Renal biopsy was done; when indicated in selected patients in each group.
Statistical analysis: Data were processed and analyzed using the computer program SPSS (The Statistical Package for the Social Science Program) version 15 for windows (SPSS Inc., Chicago, Illinois, USA). For quantitative variables, mean, range (as a measure of variability), and standard deviation were used. The median was also presented when considered appropriate. Frequency and percentage were presented for qualitative variable and percent for qualitative variables. Chi-square and Fisher's exact tests were used to estimate differences in qualitative variables and Mann-Whitney test was used to estimate differences in quantitative variables. A p-value of less than 0.05 was taken to indicate statistical significance.
Results
Demographic data of the study group
Ninety-eight patients were included in this study; they represent all SLE patients presented to the outpatient clinic or admitted to the rheumatology ward, rheumatology and rehabilitation department, Cairo University Hospitals from 1st July to 31st December 2010. All patients were screened for HCV antibody. HCV antibodies were present in 20/98 (20.4%) SLE patients (HCV/SLE group), and were absent in 78/98 (79.6%) patients (non-HCV/SLE). HCV-RNA (PCR) was detected in 8/20 (40% of the HCV antibody positive and 8.2% of the total SLE patients) while the viremia was below the detection level in 12 (60%) of the positive HCV antibody patients. Six patients of (HCV/SLE group) were recruited from the inpatient department (30%) and the rest 14/20 (70%) are recruited from the outpatient clinic. History of blood transfusion was obtained from 5/20 (25%) patients with HCV/SLE and from 26/78 (33.3%) patients with non-HCV/SLE. Statistically significant differences were found between the age and SLE disease duration of patients in both groups. Patients with HCV/SLE were older and were suffering from SLE for a longer duration than patients with non-HCV/SLE (Table 1 ).
Clinical and laboratory parameters of the study group
Comparison between the clinical features of the disease; classified according to the system involved in both groups and their statistical significance are shown in (Table 2) . Statistically higher cardiac manifestations and fundus abnormalities were found in the HCV/SLE group. Carditis was found in 6/20 (30%) and pericardial effusion in 5/20 (25%) of the HCV/ SLE group compared to 10/78 (12.8%) and 12/78 (15.45) in the non-HCV/SLE respectively. Retinal vasculitis on fundus examination was detected in 2/20 (10%), optic atrophy in 1/ 20 (5%), maculopathy in 1/20 (5%) and papilledema in 1/20 (5%) in the HCV/SLE patients compared to 2/78 (2.6%), 0/ 78 (0%), 2/78 (2.6%) and 0/78 (0%) in the non-HCV/SLE patients, respectively. On the other hand, the mucocutaneous manifestations were statistically higher in the non HCV/SLE group. Mucosal ulcers were found in 11/20 (55%), skin rash in 12/20 (60%), photosensitivity in 14/20 (70%) and alopecia in 7/20 (35%) in the HCV/SLE patients compared to 46/78 (59%), 54/78 (69.2%), 56/78 (71.8%) and 43/78 (55.1%) in the non-HCV/SLE patients, respectively. Although there was no statistical difference as regards the prevalence of the musculoskeletal manifestations between groups, arthralgia and arthritis tend to be higher in the HCV/SLE patients (95%, 85%) compared to the non-HCV/SLE patients (79.5% and 78.2%), respectively. Abdominal ultrasound showed evidence of nephropathy in 3/20 patients (15%) in HCV/SLE group versus 18/78 patients (23.1%) in the non-HCV/SLE group with no statistically significant difference between the groups, and no cirrhosis was detected in all patients of both groups. Laboratory tests that reflected the liver function were not statistically different between both groups (Table 3) .
ANA testing was positive in all our patients. Anti-DNA positivity was significantly lower in patients with HCV/SLE (p < 0.05). DNA antibodies were found in 11/20 (55%) of patients in HCV/SLE group compared to 60/78 (76.9%) in patients with non-HCV/SLE. No statistically significant difference was found between the two groups as regards ANA titer, complement component positivity or anticardiolipin positivity (Table 4 ). Significantly lower number of patients in the HCV/SLE group was on oral steroids than patients in the non-HCV/ SLE group. Table 5 shows the number and percentage of patients in each group according to the different treatment modalities used in their management.
Discussion
The global prevalence of HCV has been estimated of nearly 3%, with a substantial geographical variation [20] . Many of this estimates, came from the prevalence rates for HCV infection in blood donors; however, these prevalence rates determined from blood donors probably underestimate the HCV prevalence in the general population [21] . A national US survey found a prevalence rate more than fourfold higher in general population than in voluntary blood donors (1.8% vs. 0.4%), [22, 23] .
Autoimmunity and viral infections are closely related. Viruses in general and HCV in particular has been proposed as possible etiologic or triggering factors of many systemic autoimmune rheumatic diseases; most of the previous studies discussed the rheumatic manifestations as a part of the extrahepatic manifestations of chronic HCV infection [6, [24] [25] [26] [27] [28] . In this study we studied the prevalence of HCV antibodies among patients with SLE and evaluated the impact of the presence of chronic HCV infection on the SLE disease expression, through comparison of the demographic data, clinical manifestations and disease activity (SLEDAI score) among patients with HCV/SLE and non-HCV/SLE.
HCV antibodies were present in 20/98 (20.4%) SLE patients (HCV/SLE group), and were absent in 78/98 (79.6%) patients (non-HCV/SLE), of them active viremia (HCV-RNA) was detected in 8/98 (40% of the HCV antibody positive and 8.2% of the studied SLE patients) while the viremia was below the detection level in 12 (60%) of the positive HCV antibody patients. In a recent study in our department, HCV antibodies were found in 6.7% among patients with SLE admitted to the rheumatology ward, Cairo University Hospitals, Egypt [6] . This finding indicated that most patients of SLE and associated anti-HCV antibodies were recruited from the outpatient clinic and that the association between HCV infection and SLE does not imply increased SLE disease [12, 29, 30] . Antibodies to HCV were present in 18/134 Spanish patients with SLE (13%); of them active viremia was detected in 15 SLE patients (11%) [7] .These divergences could be attributed to the variability in the prevalence of HCV infection among the different geographic areas and even to different infection control practices in these areas.
History of blood transfusion was not different (p = 0.4) between the two groups; it was obtained from 5/20 (25%) patients with HCV/SLE and from 26/78 (33.3%) patients with non-HCV/SLE. Patients with HCV/SLE were older (p < 0.003) and were suffering from SLE for a longer duration (p < 0.001) than patients with non-HCV/SLE. In a previous study on systemic autoimmune disease (SAD) in general, associated with HCV, the authors found that SAD-HCV patients presented a specific epidemiological profile with a lower female: male ratio and an older age at diagnosis of SAD [7] . In this study, there was no statistical difference between the genders of patients of both SLE groups. The most frequent clinical manifestations in the HCV/SLE patients were the musculoskeletal (100%), hematologic (85%) followed by the mucocutaneous and constitutional manifestations, each in 80%. On the other hand, the most frequent manifestations in the non-HCV/SLE patients were the musculoskeletal (97.4%), followed by the hematologic and mucocutaneous manifestations, each in 93.6%. Statistically higher cardiac manifestations (carditis and pericardial effusion) and fundus examination abnormalities (retinal vasculitis, maculopathy, optic atrophy and papilledema) were found in the HCV/SLE group, while the mucocutaneous manifestations (mucosal ulcers, skin rash, photosensitivity and alopecia) were statistically higher in the non HCV/SLE group. Although there was no statistical difference as regards the prevalence of the musculoskeletal manifestations between groups, arthralgia and arthritis tend to be higher in the HCV/SLE patients (95%, 85%) compared to the non-HCV/SLE patients (79.5% and 78.2%), (p = 0.1 and 0.7) respectively. Laboratory tests that reflected the liver function were not statistically different between both groups ( Table 3 ). The absence of significant difference in all the routine laboratory tests of the liver function between the groups reflects the fact that chronic HCV infection may remain asymptomatic and could present with normal liver functions.
ANA positivity was found in 100% of the patients in both groups, while anti-DNA antibodies were detected less frequently in patients with HCV/SLE 55% compared to 76.9% of patients with non-HCV/SLE group (p < 0.05). Similar results were found in other previous studies [31, 32] . No statistically significant difference was found between the two groups as regards ANA titer, complement component positivity or anticardiolipin positivity (Table 4 ). On assessing the global disease activity using the SLEDAI score, there were no statistical differences between the numbers of patients with various grades of score. In addition significantly lower number of patients in the HCV/SLE group was on oral steroids than patients in the non-HCV/SLE group (Table 5) . On conclusion, HCV antibodies and active HCV viremia were found in 20.4% and 8.2% respectively among SLE patients. Patients with SLE and concomitant HCV infection were old aged, have longer disease duration, less frequent mucocutaneous manifestations, higher percentage of cardiac manifestations, higher percentage of fundus abnormalities, lower doses of steroid use, milder disease activity, higher damage index and less frequent anti-ds-DNA positivity than SLE patients without concomitant HCV infection.
